Thrombotic Microangiopathies and the Kidney

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Thrombotic microangiopathy (TMA) is characterized by endothelial injury, microangiopathic hemolytic anemia, thrombocytopenia, and end-organ ischemia.
• TMAs can present as renal-limited disease without systemic symptoms.
• Complement activation is a central mechanism in TMA, with variable involvement across etiologies.

Purpose of the Study:

• To review the pathology, mechanisms, diagnosis, and treatment of various TMA etiologies.
• To define essential complement evaluations for TMA patients.
• To highlight current and emerging complement therapies for TMAs.

Main Methods:

• Systematic review of literature on TMA pathology and mechanisms.
• Analysis of diagnostic workup strategies for TMAs.
• Evaluation of complement-mediated pathways and therapeutic interventions.

Main Results:

• TMA pathogenesis involves complex interactions between complement, neutrophils, and coagulation.
• Thorough clinical and laboratory evaluation is critical for accurate TMA diagnosis.
• Timely diagnosis and management are crucial to reduce morbidity, mortality, and prevent end-stage kidney disease.

Conclusions:

• Complement activation plays a pivotal role in diverse TMA presentations.
• Comprehensive complement assessment guides targeted therapy selection.
• Advances in complement inhibition offer promising treatment options for TMAs.